Shares of ABIOMED, Inc. (NASDAQ:ABMD) have been assigned an average rating of “Buy” from the eleven brokerages that are presently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $363.14.

A number of research analysts recently weighed in on the company. Zacks Investment Research cut ABIOMED from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 3rd. BidaskClub cut ABIOMED from a “strong-buy” rating to a “buy” rating in a report on Monday, June 18th. Piper Jaffray Companies lifted their target price on ABIOMED from $360.00 to $480.00 and gave the company an “overweight” rating in a report on Friday, June 22nd. Finally, ValuEngine cut ABIOMED from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 18th.

In other ABIOMED news, VP Michael G. Howley sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $432.50, for a total value of $4,325,000.00. Following the transaction, the vice president now directly owns 48,954 shares of the company’s stock, valued at $21,172,605. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO David M. Weber sold 19,282 shares of the firm’s stock in a transaction dated Monday, July 30th. The shares were sold at an average price of $356.77, for a total value of $6,879,239.14. Following the completion of the transaction, the chief operating officer now directly owns 167,124 shares in the company, valued at $59,624,829.48. The disclosure for this sale can be found here. Insiders sold 33,722 shares of company stock worth $12,958,039 in the last quarter. 3.50% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN raised its position in ABIOMED by 65.0% in the second quarter. Wells Fargo & Company MN now owns 134,542 shares of the medical equipment provider’s stock valued at $55,034,000 after purchasing an additional 52,986 shares during the period. Private Advisor Group LLC purchased a new position in ABIOMED in the second quarter valued at about $1,515,000. Columbus Circle Investors raised its position in ABIOMED by 179.7% in the second quarter. Columbus Circle Investors now owns 64,442 shares of the medical equipment provider’s stock valued at $26,360,000 after purchasing an additional 41,403 shares during the period. Bank of Montreal Can purchased a new position in ABIOMED in the second quarter valued at about $11,530,000. Finally, Janney Montgomery Scott LLC raised its position in ABIOMED by 16.3% in the second quarter. Janney Montgomery Scott LLC now owns 2,039 shares of the medical equipment provider’s stock valued at $834,000 after purchasing an additional 286 shares during the period. 86.21% of the stock is currently owned by institutional investors.

ABIOMED stock traded down $1.81 during midday trading on Friday, reaching $442.89. The stock had a trading volume of 620,900 shares, compared to its average volume of 631,732. ABIOMED has a twelve month low of $161.60 and a twelve month high of $454.00. The stock has a market capitalization of $19.81 billion, a P/E ratio of 182.93, a PEG ratio of 4.72 and a beta of -0.07.

ABIOMED (NASDAQ:ABMD) last issued its earnings results on Thursday, July 26th. The medical equipment provider reported $1.95 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.80 by $1.15. ABIOMED had a return on equity of 18.91% and a net margin of 25.71%. The firm had revenue of $180.01 million for the quarter, compared to analysts’ expectations of $173.87 million. During the same quarter last year, the firm earned $0.82 earnings per share. The firm’s revenue for the quarter was up 35.9% compared to the same quarter last year. analysts predict that ABIOMED will post 3.46 EPS for the current fiscal year.

ABIOMED Company Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

See Also: What is the NASDAQ?

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.